Temporary implantable nitinol device for benign prostatic hyperplasia-related lower urinary tract symptoms: over 48-month results

Amparore D, De Cillis S, Schulman C et al. Minerva Urol Nephrol. 2023;75(6):743-751.

The iTind procedure group maintained a significant improvement in symptoms after more than 48 months, with a -45.3% ($P < 0.0001$) reduction in IPSS compared to baseline (Intention-to-treat analysis).



Abbreviations: IPSS (International Prostate Symptom Score); QoL (Quality of Life); Qmax (Maximum urinary flow rate).

Objective

To assess through over 48-month (50–79 months) outcomes of the iTind procedure in patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) in a prospective, single-arm, multicenter, international study.

Results

- A total of 81 men were enrolled; 41 patients remained past 48 months. Due to COVID-19, in-person visits were replaced with a single phone evaluation at 50–79 months post-operation. Data were grouped under a single timepoint “over 48 months”.
- The iTind procedure significantly improved symptoms (intention-to-treat analysis), with Quality of Life (QoL) increasing by 45.1% ($P < 0.0001$) from baseline to over 48 months post-procedure.
- No complications or additional medication needed from 48 to 79 months.
- Surgical re-treatment rate was 4% beyond 48 months.

Conclusion

The iTind procedure provided significant and long-lasting symptom relief, as well as improved quality of life for up to and beyond 48 months, with no late-stage complications.

Product: The iTind Procedure.

Link to Publication

OLYMPUS EUROPA SE & CO. KG
Postbox 10 49 08, 20034 Hamburg, Germany
Wendenstrasse 20, 20097 Hamburg, Germany
Phone: +49 40 23773-0, Fax: +49 40 233765
www.olympus-europa.com

As medical knowledge is constantly growing, technical modifications or changes of the product design, product specifications, accessories, and service offerings may be required. Medical devices listed may not be available for sale in all countries.

M/S S00725 EN V01• 09/25 • OEKG
Olympus Scientific Affairs